Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Zevra Therapeutics logo — A Rare Approach to Therapeutics

Zevra Therapeutics

A Rare Approach to Therapeutics

Founded 2006 United States Celebration, United States 71 employees Post Ipo Debt Total: $213.75M Biotechnology, Health and Wellness +1

General Information

Company Name Zevra Therapeutics
Founded Year 2006
Location United States Celebration, United States +4
Employees 71
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Post Ipo Debt
Social

Get notified when Zevra Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Zevra Therapeutics

Zevra Therapeutics is a biotechnology and pharmaceutical company, founded in 2006 and headquartered in the United States. The company's slogan, "A Rare Approach to Therapeutics," reflects its focus on rare disease therapeutics. Zevra Therapeutics is committed to leveraging scientific innovation to address significant unmet needs in healthcare, actively involving key stakeholders such as thought leaders, physicians, patients, care partners, and advocacy groups in its clinical and regulatory development strategies. Zevra Therapeutics sets itself apart with its agility and fearlessness in pushing boundaries to advance new therapies. The company emphasizes its ability to develop creative solutions and forge new pathways to success in drug development. Its commitment to following data without bias and maintaining transparent narratives has enabled Zevra Therapeutics to overcome complex development challenges, ultimately making much-needed therapies available to patients. Notably, Zevra Therapeutics secured a $60.00M Post-IPO Debt investment on 10 April 2024, demonstrating investor confidence in the company's mission. This investment came from HealthCare Royalty Partners and Perceptive Advisors, prominent names in the investment landscape. Zevra Therapeutics' innovative and patient-centric approach positions it as a promising player in the field of rare disease therapeutics, with the potential to bring meaningful improvement to patients' lives.

Taxonomy: rare disease therapeutics, biopharmaceutical company, drug development, clinical and regulatory strategies, Ligand Activated Therapy, safer opioid pain relievers, CNS diseases, patent-applied technology, drug discovery, development-stage company, innovative therapies

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt •••••• 2
Investor Investor
10 Apr 2024
Post-IPO Debt •••••• - 01 Dec 2019
Venture Round •••••• - 04 Mar 2015
Debt Financing •••••• 1 •••• •••• 04 Jun 2014
Debt Financing •••••• - 30 May 2013

View All 8 Funding Rounds

Zevra Therapeutics Alternatives & Competitors

Zevra Therapeutics vs
Seachaid Pharmaceuticals
Seachaid Pharmaceuticals

Bringing advanced therapies to life, enabling patients to recover at home after shorter hospital sta...

2-10 employees
Biotechnology, Health Care
Zevra Therapeutics vs
Bright Angel Therapeutics
Bright Angel Therapeutics Canada

Targeting Antifungal Resistance

Seed
4 employees
Biotechnology
Compare Zevra Therapeutics vs Bright Angel Therapeutics
Zevra Therapeutics vs
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. United States

A clinical stage pharmaceutical company developing innovative treatments for neurological disease.

Series C
22 employees
Biotechnology, Health Care
Compare Zevra Therapeutics vs Cerebral Therapeutics, Inc.
Also compare with: Zevra Therapeutics vs PDC Therapeutics PDC Therapeutics

FAQ About Zevra Therapeutics

A Rare Approach to Therapeutics
Zevra Therapeutics was founded in 2006.
Zevra Therapeutics is headquartered in Celebration, United States.
Zevra Therapeutics operates in the following industries: Biotechnology, Health and Wellness, Pharmaceutical.
Zevra Therapeutics has approximately 71 employees.
Zevra Therapeutics has completed 8 funding rounds, raising a total of $213.75M. The latest funding stage is Post Ipo Debt.
Top alternatives and competitors to Zevra Therapeutics include Seachaid Pharmaceuticals, Bright Angel Therapeutics, Cerebral Therapeutics, Inc., PDC Therapeutics, Blueberry Therapeutics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Zevra Therapeutics and Seachaid Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Zevra Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy